NUDT16P1

Across TCGA pan-cancer cohorts, NUDT16P1 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of NUDT16P1’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where NUDT16P1 RNA is repressed in tumor relative to normal tissue. In most cancer types NUDT16P1 is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

THCA, STAD, and BLCA are the cancer types where NUDT16P1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NUDT16P1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−1.067	<.001	10	view →
STAD	Male	All	+0.953	<.001	5	view →
BLCA	All	All	+0.778	.014	5	view →
KIRC	All	All	−0.225	.008	4	view →
LIHC	All	II,III,IV	−0.766	.014	2	view →
BRCA	All	IV	+0.754	.018	2	view →
LUAD	Male	All	+0.382	.011	2	view →
LUSC	All	II,III,IV	−0.672	.021	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

NUDT16P1–THCA

Open the THCA breakdown →